KORU Medical Systems Inc. Common Stock (DE) (KRMD)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look for durable earning power bought at a sensible price. KORU Medical sells the FREEDOM infusion system into a narrow, chronic subcutaneous drug delivery market. With only 73 employees and no consistent profits, I cannot call the moat proven. The financial record is improving but still uneven. In fiscal FY2023, the year ended 2023-12-31, revenue was $28.5M and net income was -$13.7M. In fiscal FY2024, the year ended 2024-12-31, revenue was $33.6M and net income was -$6.1M. In fiscal FY2025, the year ended 2025-12-31, revenue was $41.1M and net income was -$2.6M. So revenue is moving up and losses are shrinking. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $12.0M and net income was $252,449, with diluted EPS of $0.01—a welcome first sign of profitability, but one quarter does not make a trend. The balance sheet looks reasonable: debt-to-equity is 0.18 and the FairStock Altman Z-Score is 7.79, with a Piotroski F-Score of 6/9. Yet trailing free cash flow is only $242,898, a FairStock FCF yield of 0.2%, so cash generation is thin. At the 2026-10-13 close of $3.00, the FairStock P/B is 7.69 and P/E is -75.00 because earnings are still negative. The FairStock score is 45/100, and there is no Peter Lynch category because of losses in each of the last four years. I would watch for repeat profitability and stronger free cash flow. The price may reflect hope, but Graham's margin of safety is not obvious.

In plain English: KORU Medical makes a small device system that delivers medicine under the skin for people with long-term illnesses. Sales are growing, but the company has lost money in recent years; it just had a small profit in the latest quarter, so the business still has a lot to prove. At $3.00 a share, the price looks speculative rather than clearly cheap, because profits and cash generation are still tiny.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer